iRhythm Technologies has announced it completed raising $17 million in series E financing.
iRhythm, headquartered in San Francisco, is a privately held healthcare information services company that focuses on the management of cardiac arrhythmia information.
The financing round was led by Novo A/S, a global life science investment firm.
Norwest Venture Partners, which led iRhythm’s series D financing, also participated in the oversubscribed round.
iRhythm indicated it will use the proceeds from the series E financing round to accelerate market growth for its ZIO Service, a long-term, continuous cardiac monitoring option expand technology; for development; and to continue to establish clinical evidence supporting ZIO Service.